CureVac N.V. (5CV.F)
EUR 2.72
(-2.01%)
EUR 2.72
(-2.01%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 36.81 Million EUR | -0.77% |
| 2022 | 37.1 Million EUR | 45.95% |
| 2021 | 25.42 Million EUR | -5.33% |
| 2020 | 26.85 Million EUR | -65.19% |
| 2019 | 77.14 Million EUR | 0.0% |
| 2018 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 33.96 Million EUR | 0.0% |
| 2024 Q1 | 35.55 Million EUR | 0.0% |
| 2023 Q2 | 35.27 Million EUR | -2.25% |
| 2023 FY | 36.81 Million EUR | -0.77% |
| 2023 Q1 | 36.08 Million USD | -2.75% |
| 2023 Q3 | 36.58 Million EUR | 3.7% |
| 2023 Q4 | 36.81 Million EUR | 0.65% |
| 2022 Q3 | 36.6 Million EUR | 1.89% |
| 2022 Q2 | 35.93 Million EUR | -1.69% |
| 2022 Q1 | 36.55 Million EUR | 43.77% |
| 2022 FY | 37.1 Million EUR | 45.95% |
| 2022 Q4 | 37.1 Million EUR | 1.36% |
| 2021 Q4 | 25.42 Million EUR | -52.22% |
| 2021 Q3 | 53.21 Million EUR | 106.04% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 FY | 25.42 Million EUR | -5.33% |
| 2021 Q2 | 25.82 Million EUR | 0.0% |
| 2020 Q1 | 96.39 Million EUR | 24.96% |
| 2020 Q4 | 26.85 Million EUR | -3.14% |
| 2020 Q3 | 27.72 Million EUR | 0.0% |
| 2020 Q2 | - EUR | -100.0% |
| 2020 FY | 26.85 Million EUR | -65.19% |
| 2019 Q1 | - EUR | 0.0% |
| 2019 FY | 77.14 Million EUR | 0.0% |
| 2019 Q4 | 77.14 Million EUR | 0.0% |
| 2018 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| BioNTech SE | 191 Million EUR | 80.723% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 90.241% |
| Biotest Aktiengesellschaft | 377.3 Million EUR | 90.241% |
| BRAIN Biotech AG | 25.19 Million EUR | -46.148% |
| Formycon AG | 7.81 Million EUR | -371.132% |
| Heidelberg Pharma AG | 70.4 Thousand EUR | -52194.516% |
| Medigene AG | 2.03 Million EUR | -1708.399% |